已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study

医学 苯达莫司汀 布苏尔班 内科学 氟达拉滨 全身照射 白血病 胃肠病学 外科 移植 环磷酰胺 耐火材料(行星科学) 造血干细胞移植 急性白血病 挽救疗法 养生 化疗 移植物抗宿主病 慢性淋巴细胞白血病 物理 天体生物学
作者
Ivan Moiseev,Sergey N. Bondarenko,Elena Morozova,Yulia Vlasova,Anna A. Dotsenko,Olga Epifanovskaya,Elena V. Babenko,Anna Botina,Vadim Baykov,Е. А. Суркова,С. В. Лапин,Anastasiya Beynarovich,E. Borzenkova,Oleg Golosgchapov,Mikhail M. Kanunnikov,Olga Kudyasheva,Varvara N. Ovechkina,Olga V. Pirogova,Valentina V. Porunova,Tatiana Rudakova
出处
期刊: [Elsevier BV]
卷期号:27 (7): 601.e1-601.e7 被引量:6
标识
DOI:10.1016/j.jtct.2021.03.032
摘要

The prognosis of acute leukemia refractory to induction chemotherapy or immunotherapy is dismal. Salvage allogeneic hematopoietic stem cell transplantation (HSCT) is widely used option for these patients, but only 10% to 15% of patients are cured by the procedure. Preclinical studies indicate that substitution of post-transplantation cyclophosphamide with bendamustine (PTB) in a prophylaxis regimen may be associated with an augmented graft-versus-leukemia (GVL) reaction. The aim of this study was to establish the optimal dose of PTB and evaluate the antileukemic effect of HSCT with this type of graft-versus-host disease (GVHD) prophylaxis. In the prospective trial (NCT02799147), PTB was administered in doses of 140, 100, and 70 mg/m2 on days +3 and +4. Myeloablative conditioning with fludarabine and oral busulfan was provided to all patients. The first 12 patients received single-agent PTB, and subsequent patients received combination therapy with tacrolimus and mycophenolate mofetil (MMF). Inclusion criteria were acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) refractory to at least one induction course of chemotherapy or target therapy and ≥5% clonal blasts in the bone marrow. The study cohort comprised 22 patients with AML and 5 with ALL. Seven patients were enrolled in the 140 mg/m2 group (due to a stopping rule), and 10 each were enrolled in the 100 mg/m2 and 70 mg/m2 groups. Primary refractory disease was documented in 41% of the patients, and secondary refractory was documented in 59%. The median blast count in the bone marrow at the start of the conditioning was 18% (range, 6% to 97%). Transplantation was performed with a matched sibling donor in 5 patients, a matched or mismatched unrelated donor in 15, and a haploidentical donor in 7. Engraftment was documented in 93% of the patients, including 89% with complete remission and 63% without measurable residual disease. After PTB prophylaxis, we observed an unusual complication, a cytokine release syndrome (CRS), in 70% of the patients, including grade 3 to 5 CRS in 44%. The most frequent clinical symptoms included high fever in 67% of patients, abnormal liver function tests in 67%, pancreatitis in 63%, skin vasculitis in 56%, enterocolitis in 48%, inflammation of oral mucosa in 37%, disseminated intravascular coagulation in 37%, and central nervous system toxicity in 26%. The development of CRS was associated with use of an HLA-mismatched donor (75% versus 20%; P = .0043). Classic acute GVHD was documented in 44% of the patients. Grade II-IV acute GVHD was associated with grade 3 to 5 CRS (67% versus 25%; P = .031). Moderate and severe chronic GVHD in the 100-day survivors were more often observed after single-agent PTB than after the combination immunosuppression (100% versus 18%; P = .002). A relatively low relapse rate was observed for this patient population. Three-year overall survival was 28% (95% confidence interval [CI], 13% to 46%), and event-free survival was 29% (95% CI, 13% to 46%). Nonrelapse mortality was 46% (95% CI, 25% to 64%), and the cumulative incidence of relapse was 26% (95% CI, 11% to 44%). No relapses were documented after day +100. There were no statistically significant differences among the dose groups (P = .3481); however, survival was higher in the 100 mg/kg group. Survival was higher in patients with AML compared with those with ALL (35% versus 0%; P = .0157). PTB represents a promising option to augment the GVL effect in refractory AML; however, the high CRS-associated mortality necessitates additional studies to reduce the risk of this complication. Thus, routine clinical application of PTB cannot be currently recommended. Combination immunosuppression with tacrolimus and MMF partially ameliorates these complications, at least in the setting of HLA-matched allografts. Biological mechanisms of CRS and GVL after PTB require further elucidation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿馅儿完成签到 ,获得积分10
1秒前
山山而川完成签到 ,获得积分10
1秒前
as发布了新的文献求助10
3秒前
5秒前
未见山发布了新的文献求助30
5秒前
5秒前
zqzq完成签到,获得积分10
7秒前
8秒前
Lucas的应助被南歪歪采纳,获得10
8秒前
8秒前
10秒前
fuli发布了新的文献求助10
11秒前
彦祖发布了新的文献求助10
13秒前
13秒前
克里斯蒂娜完成签到 ,获得积分10
13秒前
yuquan关注了科研通微信公众号
14秒前
九九九发布了新的文献求助10
17秒前
17秒前
17秒前
17秒前
as完成签到,获得积分20
18秒前
所所的应助被夏侯乌采纳,获得10
20秒前
喜悦寒凝发布了新的文献求助10
21秒前
热情钵钵鸡完成签到,获得积分10
22秒前
九九九完成签到,获得积分20
24秒前
小二郎的应助被Dyying采纳,获得10
25秒前
在水一方的应助被lcy采纳,获得10
25秒前
26秒前
无极微光的应助被TOMORROW采纳,获得20
27秒前
奋斗灵安完成签到,获得积分10
27秒前
闪闪的硬币完成签到 ,获得积分10
27秒前
时倾完成签到 ,获得积分10
29秒前
30秒前
所所的应助被kjh采纳,获得10
30秒前
badada完成签到 ,获得积分10
32秒前
33秒前
34秒前
完美世界的应助被喜悦寒凝采纳,获得10
36秒前
37秒前
大横按的痛完成签到,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184619
求助须知:如何正确求助?哪些是违规求助? 9573576
关于积分的说明 21832380
捐赠科研通 7781845
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003